Podcasts about Sukumar

On February 1st, India's finance minister Nirmala Sitharaman presented her eighth Budget of the Modi era. This year's budget was tabled at a precarious economic juncture, for India and for the world. India has been challenged by slowing growth, persistent inflation, and global uncertainties motivated in part by the return of Donald Trump to the White House just a few weeks ago.So, how has the finance minister approached this delicate moment? What are the government's priorities for the coming fiscal year? And has it made the tough decisions that could revive underlying animal spirits?To discuss these and many other questions, Milan is joined on the podcast this week by Sukumar Ranganathan, editor-in-chief of the Hindustan Times.Long-time listeners will know that Sukumar has regularly appeared on the show to share his insights on India's political economy with us. On this week's show, Milan and Sukumar discuss India's worrying growth slowdown, the government's pitch for deregulation, and a generous tax cut for the middle class. Plus, the two discuss the potential impacts of Trump's tariffs on the Indian economy.Episode notes:1. “Anticipating the Unintended,” issue 287, February 2, 2025.2. Roshan Kishore, “What the budget does for politics,” Hindustan Times, February 2, 2025.3. Roshan Kishore, “What the budget does for demand,” Hindustan Times, February 2, 2025.4. Roshan Kishore, “What the budget does for the fisc,” Hindustan Times, February 2, 2025.5. Roshan Kishore, “What the budget 2025 means for economic reforms,” Hindustan Times, February 2, 2025.6. “Previewing India's 2024 General Election (with Sukumar Ranganathan),” Grand Tamasha, April 17, 2024.

Rathnavelu, the cinematographer behind iconic movies like Rangasthalam and 1: Nenokkadine, enters the Permit Room and talks about studying in Madras Film Institute, shooting Sukumar's movies, his favourite cinematographers, breaks down some scenes, his guru - Rajiv Menon, Aishwarya Rai loving his work, working with Sachin Tendulkar, MS Dhoni and much more. Chapters: 00:00 - Why do cinematographers look young?03:29 - Studying in Madras Film Institute08:35 - Does he use the phone camera?11:21 - American Cinematographer magazine14:17 - His favourite cinematographers21:26 - When did he fall in love with cinematography?24:34 - Creative decisions in Rangasthalam31:53 - His guru - Rajiv Menon37:02 - Discussing 1: Nenokkadine's interval42:26 - What is his personal aesthetic?48:49 - Breaking down 1: Nenokkadine scene54:01 - What is the future of cinematography with AI?56:42 - Cricket and living in Chennai1:02:45 - Shooting ads with Sachin Tendulkar and MS Dhoni1:08:58 - Do cinematographers meet each other?1:14:54 - Heroines want to be in cinematographer's good books1:17:21 - Disappointed with ID photos1:20:40 - Does he want to become a director?1:28:31 - Movies he will take to Mars1:31:13 - Drinking career1:32:18 - Why is cricket telecast better abroad?1:33:51 - We should start Hyderabad Film Festival1:37:57 - Advice for aspiring cinematographers1:39:50 - Four aspects

Dr. Jasmine Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and BRCA1/2 mutations, including how to identify patients who should receive genetic testing and the significant survival benefits of olaparib that emerged from the OlympiA trial. TRANSCRIPT Dr. Jasmine Sukumar: Hello, I'm Dr. Jasmine Sukumar, your guest host of the ASCO Daily News Podcast today. I'm an assistant professor and breast medical oncologist at the University of Texas MD Anderson Cancer Center. On today's episode, we'll be exploring advances in adjuvant therapy for high-risk early breast cancer in people with BRCA1/2 germline mutations. Joining me for this discussion is Dr. Dionisa Quiroga, an assistant professor and breast medical oncologist at the Ohio State University Comprehensive Cancer Center.  Our full disclosures are available in the transcript of this episode.  Dr. Quiroga, it's great to have you on the podcast. Thanks for being here. Dr. Dionisia Quiroga: Thank you. Looking forward to discussing this important topic. Dr. Jasmine Sukumar: Let's start by going over who should be tested for BRCA1/2 genetic mutations. How do you identify patients with breast cancer in your clinic who should be offered BRCA1/2 genetic testing? Dr. Dionisia Quiroga: So, guidelines on who to offer testing to somewhat differ between organizations at this point. I would say, generally, I do follow our current ASCO-Society of Surgical Oncology (SSO) Guidelines, though. Those guidelines recommend that BRCA1/2 mutation testing be offered to all patients who are diagnosed with breast cancer and are 65 years old or younger. For those that are older than 65 years old, there are additional factors to really take into account to decide on who to recommend testing for. Some of this has to do with personal and family history as well as ancestry. The NCCN also has their own specific guidelines for who to offer testing to. For example, people assigned male at birth; those who are found to have a second breast primary; those who are diagnosed at a young age; and those with significant family history should also be offered BRCA1/2 testing.  I think, very important for our discussion today, ASCO and SSO also made a very important point that all patients who may be eligible for PARP inhibitor therapy should be offered testing. So clearly this includes a large amount of our patient population. In my practice, we often refer to our Cancer Genetics Program. We're fortunate to have many experienced genetic counselors who can complete pre-test and post-test counseling with our patients. However, in settings where this may not be accessible to patients, it can also be appropriate for oncology providers to order the testing and ideally perform some of this counseling as well. Dr. Jasmine Sukumar: Thank you Dr. Quiroga. Let's next review where we are in current clinical practice guidelines. What current options do we have for adjuvant therapy specific to people with high-risk early breast cancer and BRCA1/2 genetic mutations? Dr. Dionisia Quiroga: Our current guidelines recommend adjuvant olaparib for one year for individuals with HER2-negative high risk breast cancer. This approval largely came from the data and the results of the OlympiA trial. This was a prospective phase 3, double blind, randomized clinical trial. It enrolled patients who had been diagnosed with HER2-negative early-stage breast cancer who also carried germline pathogenic or likely pathogenic variants of either the BRCA1 and/or BRCA2 genes. The disease also had to be considered high-risk and there were several criteria that had to be evaluated to deem whether or not these patients were high-risk. For example, those who are treated with neoadjuvant chemotherapy, if they had disease that was triple-negative, they needed to have some level of invasive residual disease at time of surgery. Alternatively, if the disease was hormone receptor-positive, they needed to have residual disease and a calculated CPS + EG score of 3 or higher. This scoring system is something that estimates relapse probability on the basis of clinical and pathologic stage, ER status, and histologic grade, and this will give you a score ranging from 0 to 6. In general, the higher the score, the worse the prognosis. This calculator though is available to the public online to allow providers to calculate this risk.  For the subset of patients who received adjuvant chemotherapy, for them to qualify for the OlympiA trial, if they had triple-negative disease, they needed to have a tumor of at least 2 cm or greater and/or have positive lymph nodes for disease. For hormone receptor-positive disease that was treated with adjuvant chemotherapy, they were required to have four or more pathologically confirmed positive lymph nodes at time of surgery. From this specified pool, patients were then randomized 1:1 to get either adjuvant olaparib starting at 300 mg twice a day or a matching placebo twice a day after they had completed surgery, chemotherapy and radiation treatment if needed. Dr. Jasmine Sukumar: And what were the outcomes of this study? Dr. Dionisia Quiroga: The study ended up enrolling over 1,800 patients and from these 1,800 patients, 70% had a BRCA1 mutation while 30% had a BRCA2 mutation. About 80% of the patients had triple-negative disease compared to hormone receptor-positive disease. Interestingly, about half of all patients enrolled had received neoadjuvant chemotherapy while the other half received adjuvant chemotherapy.  Looking at the outcomes, this was overall a very positive study. We actually now have outcomes data from a median of about 6 years out. This was just reported in December at the 2024 San Antonio Breast Cancer Symposium. There was found to be a 9.4% absolute difference in six-year invasive disease-free survival favoring the olaparib arm over the placebo arm. What was also interesting is that this was consistent across multiple subgroups of patients and the benefit was really seen whether or not they had hormone receptor-positive or triple-negative disease. The absolute difference in distant disease-free survival was also high at 7.8% and additionally favored olaparib. Most importantly, there was found to be a significant overall survival benefit. The six-year overall survival was 87.5% in the olaparib group compared to 83.2% in the placebo group. This translates to about a 4.4% difference and a relative 28% overall survival benefit in using olaparib.  Now, future follow up is going to be very important. Follow up for this study is actually planned to continue out until June 2029 so we can continue to observe if these survival curves will continue to branch apart as they have so far at each follow up. And I think this is especially important for those patients diagnosed with hormone receptor-positive cancers because we know those patients are at particular risk for later recurrences.  As an additional side note, the researchers also noted that there were fewer primary malignancies in the olaparib group, not just of the breast but also primary ovarian or fallopian tube cancers as well, which is not completely surprising knowing that this drug is also heavily used and beneficial in different types of gynecologic cancers. Ultimately, the amount of adverse events reported have been low with only about 9.9% of patients receiving olaparib needing to discontinue drug due to adverse events, and this is compared to 4.2% reported in the placebo group. Dr. Jasmine Sukumar: You mentioned that the OlympiA trial showed an overall survival benefit, but interestingly the OlympiAD trial looking at olaparib versus chemotherapy in patients with advanced metastatic HER2-negative breast cancer did not show a significant overall survival benefit. Could you discuss those differences? Dr. Dionisia Quiroga: I agree, that's a very good point. So OlympiA's comparator arm was, of course, a placebo. So while this isn't the same as comparing to chemotherapy, it does still potentially suggest that there is a degree of benefit that olaparib can provide when it's introduced in the early local disease setting compared to advanced metastatic disease. I think we need more future trials looking at potential other combinations to see if we can improve the efficacy of PARP inhibitors in the metastatic setting. Dr. Jasmine Sukumar: For patients who do choose to proceed with use of adjuvant olaparib due to the promising efficacy, what side effects should oncologists counsel their patients about? Dr. Dionisia Quiroga: The most common notable side effects, I would say with olaparib and other PARP inhibitors are really cytopenias. Gastrointestinal side effects such as nausea and vomiting can occur as well as fatigue. There are some less common but potentially more serious side effects that we should counsel our patients on. This includes pneumonitis. So counseling patients on if they're short of breath or experiencing cough to let their provider know. Venous thromboembolism can also be increased rates of occurrence. And then of course myelodysplastic syndromes or acute myeloid leukemia is something that we often are concerned about. That being said, I think it should be noted that interestingly in the OlympiA trial so far, there have been less new cases of MDS and AML in the olaparib group than actually what's been reported in the placebo group at this median follow up of over six years out. So we'll need to continue to monitor this endpoint over time, but I do think this provides some reassurance. Dr. Jasmine Sukumar: Since the initiation of the OlympiA trial, other adjuvant treatments have also been studied and FDA approved for non-metastatic HER2-negative breast cancer. So for example, the CREATE-X trial established adjuvant capecitabine as an FDA approved treatment option in patients with triple-negative breast cancer who had residual disease following neoadjuvant chemotherapy. So if a patient with triple-negative breast cancer with residual disease is eligible for both adjuvant olaparib and adjuvant capecitabine treatments, how do you decide amongst the two? Dr. Dionisia Quiroga: If a patient's eligible for both, I honestly often favor olaparib, and I do this because I find the data for adjuvant olaparib a little bit more compelling. There are also differences in toxicity profile and treatment duration between the two that I think we should discuss with patients. For example, olaparib is supposed to be taken for a year total, whereas with capecitabine we typically treat for six to eight cycles with each cycle taking three weeks. There are some who may also sequence the two drugs in very high-risk disease. However, this is very much a data free zone. We don't have any current clinical trials really comparing these two or if sequencing of these agents is appropriate. So I don't currently do this in my own clinical practice. Dr. Jasmine Sukumar: Nowadays, almost all patients with stage 2 to 3 triple-negative breast cancer will be offered neoadjuvant chemotherapy plus immune checkpoint inhibitor therapy pembrolizumab per our KEYNOTE-522 trial data. With our current approach, pembrolizumab is continued into the adjuvant setting regardless of surgical outcome, so that patients receive a year total of immunotherapy. So in patients with residual disease and a BRCA germline mutation, do you suggest using adjuvant olaparib concurrently with pembrolizumab? Do we have any data to support that approach? Dr. Dionisia Quiroga: I do. I do use them concurrently. If a patient is eligible for adjuvant olaparib, I would use it the same way as if they were not on pembrolizumab. That being said, there are no large studies currently that have shown what the benefit or the toxicity of pembrolizumab plus olaparib are for early-stage disease. However, we do have some safety data of this combinatorial approach from other studies. For example, the phase 2/3 KEYLYNK-009 study showed that patients with advanced metastatic triple-negative breast cancer who were receiving concurrent pembrolizumab and olaparib had a manageable safety profile, particularly as the toxicities of these drugs alone don't tend to overlap. Dr. Jasmine Sukumar: And what about endocrine therapy for those that also have hormone receptor-positive disease? Dr. Dionisia Quiroga: Adjuvant endocrine therapy should definitely be continued while patients are on olaparib if they're hormone receptor-positive. An important component of this will also likely be ovarian suppression, which should include recommendation of risk reducing bilateral salpingo oophorectomy due to the risk of ovarian cancer development in patients who carry BRCA1/2 gene mutations. In most cases, this should happen at age 40 or before for those that carry a BRCA1 mutation, and at age 45 or prior for those with BRCA2 mutations. Dr. Jasmine Sukumar: And do you also consider adjuvant bisphosphonates in this context? Dr. Dionisia Quiroga: Yes. Like adjuvant endocrine therapy, adjuvant bisphosphonates were also instructed to be given according to standard guidelines in the OlympiA trial, so I would recommend use of bisphosphonates when indicated. You can refer to the ASCO Ontario Health Guidelines on Adjuvant Bone-Modifying Therapy Breast Cancer to guide that decision in order to utilize this due to multiple clinical benefits. It doesn't just help in terms of adjuvant breast cancer treatment but also reduction of fracture rate and down the line, improved breast cancer mortality.  Dr. Jasmine Sukumar: Particularly in hormone receptor-positive breast cancer, another adjuvant therapy option that was not available when the OlympiA trial started are the CDK4/6 inhibitors, ribociclib and abemaciclib, based on the NATALEE and monarchE studies. So how do you consider the use of these adjuvant therapy drugs in the context of olaparib and BRCA mutations? Dr. Dionisia Quiroga: Yeah, so we are definitely in a data-free zone here. And that's in part because the NATALEE and the monarchE studies are still ongoing and reporting data out at the same time that we're getting updated OlympiA data. So unlike some of our other adjuvant treatments that we discussed, where olaparib could be safely given concurrently, the risk of myelosuppression and using both a CDK4/6 inhibitor and a PARP inhibitor at the same time would be too high. In some cases, even if a patient has a BRCA1/2 mutation, they may not meet that specified inclusion criteria that OlympiA set for what they consider to be high-risk disease. And we know from the NATALEE and the monarchE trial there are also different markers that they use to denote high-risk disease. So it's possible, for example, in the NATALEE trial that looks specifically at adjuvant ribociclib, they included a much larger pool of hormone receptor-positive early-stage breast cancers, including a subset that did not have positive axillary lymph nodes.  In cases where patients would qualify for both olaparib and a CDK4/6 inhibitor, I think this is worth a nuanced discussion with our patients about the potential benefits, risks and administration of these drugs. I think another point to bring up is the cost associated with these drugs and the length of time patients will be on for, because financial toxicity is always something that we should bring up with patients as well. When sequencing these in high-risk disease, my practice is to generally favor olaparib first due to the overall survival data. There is also some data to support that patients with BRCA1/2 germline mutations may not respond quite as well to CDK4/6 inhibitors compared to those without. But again, this is still outside of the purview of current guidelines. Fortunately, we have more potential choices for patients, and that's a good thing, but shared decision making also needs to be key. Dr. Jasmine Sukumar: And while our focus today is on adjuvant treatment for people who carry germline BRCA mutations, what about other related gene mutations such as PALB2 pathogenic variant? Dr. Dionisia Quiroga: That's a great question. Clinical trials in the advanced metastatic setting have shown that there is efficacy of olaparib in the setting for PALB2 mutations. This is largely based on the TBCRC 048 phase 2 trial and that provided a Category 2B NCCN recommendation for patients with these PALB2 gene mutations. However, we're really still lacking enough clinical data for use in early-stage disease, so I don't currently use adjuvant olaparib in this case. I am definitely eager for more data in this area as the efficacy of PARP inhibitors in PALB2 gene mutations is very compelling. I think also, in the same line, there's been some data for somatic BRCA1/2 mutations in the metastatic setting, but we still have a lack of data for the early stage setting here as well. Dr. Jasmine Sukumar: Thank you Dr. Quiroga, for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Dionisia Quiroga: Thank you, Dr. Sukumar. Dr. Jasmine Sukumar: And thank you to our listeners for your time today. You'll find links to the studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Dionisa Quiroga @quirogad @quirogad.bsky.social Dr. Jasmine Sukumar @JasmineSukumar  @jasmine.sukumar.bsky.social Follow ASCO on social media:  @ASCO on X   @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn    Disclosures: Dr. Dionisia Quiroga:  No relationships to disclose Dr. Jasmine Sukumar: Honoraria: Sanofi (Immediate Family Member)  

The Epiphany of the Lord - Matthew 2:1-12 Rev. Radhika Sukumar-White (she/her) has been a Minister of the Word in the Uniting Church in Australia since 2016. A second-generation Sri Lankan Tamil Australian, she grew up in Canberra before moving to Sydney to study Physiotherapy, Music and then Theology. Radhika is interested in leading dynamic and sacred worship, preaching, teaching and walking alongside individuals in their life and faith journeys. Radhika is currently serving as Ministry Team Leader at Leichhardt Uniting Church, a young, vibrant, justice-oriented community of faith on Gadigal and Wangal land. She serves alongside her husband, who also serves as Chaplain at the University of Sydney.

Pavani Karanam enters the Permit Room and talks about how her life changed after Pushpa 2, how she auditioned for it, working with Sukumar, how Allu Arjun is on set, working on Pareshan and much more. Chapters: 00:00 - Managing Instagram fame 6:10 - Opinions on upma 10:45 - Lockdown stories 13:22 - Pareshan memories 17:41 - Quitting her job to start acting 26:47 - Auditioning for Pushpa 38:04 - Shooting for Pushpa 41:33 - How has life changed after Pushpa 2? 46:42 - How was it working with Allu Arjun? 1:00:34 - Reacting to Pushpa thumbnails 1:05:02 - Member questions 1:14:20 - School life 1:25:28 - How did parents accept her acting career? 1:35:13 - Daily life of an actor 1:45:41 - Movie recommendations 1:48:05 - What sport would she choose for a biopic? 1:51:29 - Obsessions 2:00:03 - Four aspects 2:03:39 - New year resolutions

Send us a textPushpa 2 - The Rule Movie Review! Spoilers|  Telugu | Allu Arjun | Rashmika | Fahadh Faasil! @PardesiReviews ! Kathy and Melanie review the film, Pushpa 2: The Rule, a 2024 Indian Telugu language action drama film[7] directed by Sukumar and produced by Mythri Movie Makers, in association with Sukumar Writings. The film stars Allu Arjun in the titular role, alongside Rashmika Mandanna, Fahadh Faasil, Jagapathi Babu, Dhananjaya, Rao Ramesh, Sunil and Anasuya Bharadwaj. It is the second installment in the Pushpa film series and the sequel to the 2021 film Pushpa: The Rise.#pushpa2review #Pushpa2TheRuleTraile #AlluArjun  #Pushpa2TheRule #Sukumar #RashmikaMandanna #FahadhFaasil #DSP #MythriMovieMakers #pushpa2telugu Watch  @PardesiReviews 's Spoiler Free Review: https://www.youtube.com/watch?v=_oGxDll5YJg&t=221sCinemondo is excited to announce that co-host, Burk Sauls, book, One Hundred Movies: Burk's Favorite Movies Volume 1, is available on Amazon!  https://www.amazon.com/dp/B0DML5K363?ref_=pe_93986420_774957520Get early access to these reviews by joining Patreon or our YouTube channel! YouTube Membershiphttps://www.youtube.com/channel/UCvt8UhKoTahIIRGIwxzUVVA/joinPatreonhttps://www.patreon.com/CinemondoPodcastJoin this channel to get access to fun perks like exclusive content and private Discord channel!:https://www.youtube.com/channel/UCvt8UhKoTahIIRGIwxzUVVA/joinOfficial Swag https://shop.spreadshirt.com/cinemondoNew videos daily!!Subscribe for the latest movie reviewshttps://www.youtube.com/channel/UCvt8UhKoTahIIRGIwxzUVVA?sub_confirmation=1

Uday and I talked about our thoughts on pushpa 2 directed by Sukumar , Starring Allu Arjun and Rashmika

In this episode, Sabaree, Sathish, Vaishu & Chriznill talk about Pushpa 2: the rule starring Allu Arjun, Fahad Faasil & rashmika Mandanna directed by Sukumar & music by Devi Sri Prasad (DSP). Ketutu unga feedback ah comments leh podunga. Please follow/ subscribe to our podcast. Follow us on Instagram in the below links

pWotD Episode 2774: Pushpa 2: The Rule Welcome to Popular Wiki of the Day, spotlighting Wikipedia's most visited pages, giving you a peek into what the world is curious about today.With 719,646 views on Thursday, 5 December 2024 our article of the day is Pushpa 2: The Rule.Pushpa 2: The Rule is a 2024 Indian Telugu-language action drama film directed by Sukumar and produced by Mythri Movie Makers, in association with Sukumar Writings. The film stars Allu Arjun in the titular role, alongside Rashmika Mandanna, Fahadh Faasil, Jagapathi Babu, Dhananjaya, Rao Ramesh, Sunil and Anasuya Bharadwaj. It is the second instalment in the Pushpa film series and the sequel to the 2021 film Pushpa: The Rise. The sequel was officially announced a few days prior to the original film's release in December 2021, under Pushpa 2, while the subtitle Pushpa 2: The Rule was announced in August 2022. 10% of the film's footage was initially shot back-to-back with the original film. However, Sukumar decided to alter the story, which led to the film's principal photography commencing in October 2022. The film has music composed by Devi Sri Prasad, cinematography handled by Mirosław Kuba Brożek and editing by Naveen Nooli. Made on a budget of ₹400–500 crore, the film is one of the most expensive Indian films. With a runtime of 200 minutes, it is one of the longest Indian films ever made.Pushpa 2: The Rule was released worldwide on 5 December 2024 in standard, IMAX, 4DX, D-Box and PVR ICE formats.This recording reflects the Wikipedia text as of 02:53 UTC on Friday, 6 December 2024.For the full current version of the article, see Pushpa 2: The Rule on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Mastodon at @wikioftheday@masto.ai.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm long-form Gregory.

India Directed by Sukumar

"Exploring Aarya: Allu Arjun's Iconic Romantic Drama" Sandy and Pruthvi take a nostalgic dive into Aarya, the film that redefined Allu Arjun's career and established him as the "Stylish Star." They discuss Sukumar's fresh storytelling, Devi Sri Prasad's chart-topping music, and the film's unique take on unrequited love. Join them as they unpack how Aarya struck a perfect balance between heartfelt emotions and youthful energy, making it a timeless favorite in Telugu cinema.

In this episode of Hireside Chats, we explore the transformative potential of Generative AI in talent acquisition with Sukumar Rajagopal, Founder & CEO of Tiny Magiq and a veteran in the IT services industry. Sukumar shares his insights on how Gen AI is revolutionizing recruitment processes, from automating tasks to enhancing decision-making. We also debunk common myths surrounding AI, such as fears of it replacing human recruiters or being inherently biased. Sukumar offers a glimpse into the future of AI-driven hiring systems, discussing the evolving role of human recruiters and how organizations can prepare for a seamless collaboration between AI and humans. Tune in to discover what Gen AI can—and can't—do in the realm of talent acquisition, and get a sneak peek into the innovations shaping the future of work. Guest Bio: Our guest on the show today is a visionary in the field—Sukumar Rajagopal, Founder & CEO of Tiny Magiq, a digital disruption accelerator startup that has been at the forefront of Gen AI innovation since 2015. With over 35 years of experience in the IT services industry, including his former leadership roles at Cognizant, Sukumar brings a wealth of knowledge and insights to our discussion. (01:00) Part 1: Introduction to guest and the platform (02:26) A quick introduction to everything you do at Tiny Magiq? (04:12) Part 2: Setting the Stage (04:25) Let's start with your take on the current state of Gen AI, and how close are we to realizing its full potential, especially in the realm of talent acquisition? (08:06) Can you share an example of an innovative company or two that are revolutionizing the way talent acquisition is done?  (10:12) Part 3: Busting the Myths (10:58) Myth 1: Generative AI Can Replace Human Recruiters (14:51) Myth 2: Gen AI is Biased and Discriminatory (16:58) Part 4: Vision of a Future TA System Powered by Generative AI (17:26) Do you really think that something like this will become the core of future recruiting or a future talent system or is this still  several years away ? (21:30) Part 5 : Rapid fire round  (21:52) Imagine a day without Gen AI in your work life. What would be the biggest challenge? (22:46) What are your top 3 Gen AI investments / tools in your arsenal?  (24:38) The one thing where you felt Gen AI can't do, no matter how advanced it gets? (25:48) Considering your deep roots in IT and Gen AI, if you were to compare Gen AI to a pivotal invention in history, which would it be and why? (26:44) Have you come across any individual who was anti Gen AI, who completely debunked the myth that Gen AI can do so many transformative things and you were able to transform this person's perception through your wor? (28:38) Part 6: Closing thoughts If you enjoyed this episode, leave a review or share it on your socials to help us reach as many ears as possible. So, until next time, stay tuned.

Hello good people, Welcome to the third conversation in our five episode mini-series with UME's Pulse team. Over the last two weeks we've explored generational divides and climate crisis, eco anxiety and the like.  This week another big conversation. What does it mean to keep faith in a world of racial injustice? Are people of faith in Australia today able to honestly grapple with racism in our history and our present moment? Why does it seem like the church is often no better than the rest of society in this regard? And what might it look like to continue the work of decolonising Christianity and creating anti-racist faith spaces? This is a big conversation — so much bigger than this podcast episode — but here to spark some of your thinking around these questions I'm joined by Nathan Tyson, Radhika Sukumar-White and Leisl Homes. Watch this episode on Youtube here.Download the accompanying discussion guide here. Want to reach out and let us know your thoughts or suggestions for the show? Send us a message here; we'd love to hear from you.Sign up to our mailing list:https://spiritualmisfits.com.au/Join our online Facebook community: https://www.facebook.com/groups/spiritualmisfitspodcastSupport the pod:https://spiritualmisfits.com.au/support-us/Send us an email: Spiritualmisfits@outlook.comView all episodes at: https://spiritualmisfits.buzzsprout.com

Breaking Down Silos for Alzheimer's Innovation: A Conversation with Aishu Sukumar of Gates Ventures This episode of StartUp Health NOW welcomes Aishu Sukumar of Gates Ventures in another in our series of conversations with our Alzheimer's Moonshot Impact Board. A champion for collaboration: Explore Sukumar's vision for leveraging data and fostering collaboration among Alzheimer's innovators. From research scientist to moonshot leader: Discover Sukumar's unique career path that bridges science, business, and healthcare, taking her from Harvard Medical School and Berkeley to working at startups and then to Gates Ventures. The power of a Health Moonshot Community: Learn how this initiative is uniting innovators to accelerate progress against Alzheimer's. This episode is for you if: You're passionate about finding a cure for Alzheimer's. You believe in the power of collaboration in tackling complex challenges. You're curious about the journeys of inspiring healthcare leaders. Want even more about Alzheimer's disease innovation? Learn how you can join our new Alzheimer's Moonshot Meet the first companies to join the Alzheimer's Moonshot Community Meet Phyllis Ferrell, Chief Impact Officer for StartUp Health's Alzheimer's Moonshot Join us as we explore how Aishu Sukumar's diverse background is shaping the future of Alzheimer's research as a member of our Alzheimer's Moonshot Impact Board. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox. Innovators: Health Transformer University fuels your health moonshot Funders: Become a Health Moonshot Champion

From Hinduism to Christianity with Deepa Sukumar Join Educate For Life Radio, as Kevin interviews Deepa Sukumar, former Hindu. Learn more about her testimony and how God changed her life. This episode first aired on May 28. 2024

In this episode, we dive into the cultural significance of the Kashmiri language with our special guest Sukumar Hakhoo. Join us as we explore why it's essential for the youth to embrace and preserve our beautiful linguistic heritage.

Ansira is an independent, global marketing technology and services company with clients across B2B, B2C, and B2B2C industries that leverage the company's suite of proprietary technology platforms across website, media, and channel partner marketing. Ansira guides clients operating in distributed ecosystems to connect with their customers, fostering brand loyalty by seamlessly integrating digital and physical experiences from the enterprise level to the hyper-local level. Recommending best-in-class products, Ansira also works with clients to strengthen loyalty efforts. Loyalty, incentives, and rewards all fall within the company's integrated loyalty practice.  Mark Johnson, CEO of Loyalty360, spoke with Sukumar Muthya, EVP of Integrated Loyalty at Ansira, about integrated loyalty, how brands can go beyond loyalty mechanics, and ensuring reward complexity is kept to a minimum.

In just a few days, India's eighteenth general elections will get underway with voting in the first phase kicking off on April 19. Between April 19 and June 1, India will have seven separate polling days culminating in a final counting of votes on June 4.Every single pre-election survey to date shows the ruling Bharatiya Janata Party (BJP) alliance of Prime Minister Narendra Modi winning a comfortable majority of seats in the Lok Sabha. If these predictions come to fruition, it would be the first time that a party has won three consecutive elections under the same leader since Congress during the Nehru period.To preview these elections—and what they mean for India's future—Milan is joined on the show this week by Sukumar Ranganathan, editor-in-chief of the Hindustan Times. Few people in India have observed and analyzed politics, economics, and social change as comprehensively as Sukumar.Milan and Sukumar discuss the issues animating voters this election, the state of the economy, and the significant expansion of the BJP coalition. Plus, the two discuss the opposition's struggles, the BJP's big push in the southern states, and what we know about the agenda for Modi 3.0.Episode notes:1. Milan Vaishnav, “On electoral bonds, a short-lived celebration,” Hindustan Times, February 17, 2024.2. “Decoding the Indian Economy (with Pranjul Bhandari)” Grand Tamasha, April 3, 2024.3. Sukumar Ranganathan, “Five Things with @HT_Ed,” Hindustan Times (newsletter).4. Hindustan Times, General Elections Retrospective (accessed via the HT app).

As elections approach, this is an attempt to do a short bit on Indian election history an attempt for all of us to think beyond whatsapp and a trial to let all of us know that history did exist before 2014. In the first episode of this kind, we talk about a hero unheard Sukumar Sen, the first election commissioner of India. Let's know your thoughts.

Sukumar Ramanathan has over 20 years of technology sales experience and is currently an RVP of Sales at Anaplan overseeing the west region. He and his team specifically support some of the world's leading technology, media, and telecom companies. He joins Chad Pyke on the show to talk about his career journey. In this episode you'll learn:  → The importance of repetition as a key for long term career success. → Great leaders are great listeners. When in doubt, ask others “Tell me more”.  →  Finding a mentor you want to emulate will accelerate your career.  → How to build great relationships with your stakeholders.  Visit all the pertinent links: cothryve.co/links 

Hema Sukumar, author of MINOR DISTURBANCES AT GRAND LIFE APARTMENTS.Guest Author: Hema Sukumar Twitter: @Hema_Sukumar IG: @hemasukumarwrites Books: MINOR DISTURBANCES AT GRAND LIFE APARTMENTS by Hema SukumarHost: Kate Sawyer Twitter: @katesawyer IG: @mskatesawyer Books: The Stranding by Kate Sawyer & This Family If you enjoyed this 'minisode' please do check out our full-length episodes: https://www.spreaker.com/show/novel-experienceNovel Experience with Kate Sawyer is recorded and produced by Kate Sawyer - GET IN TOUCH Twitter: @KateSawyer Instagram: @mskatesawyerTo receive transcripts and news to your inbox please SIGN UP FOR MY NEWSLETTER or visit https://www.mskatesawyer.com/novelexperiencepodcast for more information.

Radhika Sukumar-White is an ordained minister in the Uniting Church of Australia and she co-leads Leichhardt Uniting Church, a beautiful and vibrant community of faith, justice and creativity. We talk about Radhika's own story as well as some of the unique characteristics that make LUC the special place that it is and what other communities might be able to learn from their approach. Sign up to our mailing list:https://spiritualmisfits.com.au/Join our online Facebook community: https://www.facebook.com/groups/spiritualmisfitspodcastSupport the pod:https://spiritualmisfits.com.au/support-us/Send us an email: Spiritualmisfits@outlook.comView all episodes and access transcripts at: https://spiritualmisfits.buzzsprout.com

Hema Sukumar, author of MINOR DISTURBANCES AT GRAND LIFE APARTMENTS.Hema chats about:Her background in engineering and how working on a geophysical ship led to her writing her first novelWhy food plays such a huge role in her writingHow a Guardian Masterclass helped her get publishedHow she'd highly recommend booking agent 1-2-1 through Jericho writersGuest Author: Hema Sukumar Twitter: @Hema_Sukumar IG: @hemasukumarwrites Books: MINOR DISTURBANCES AT GRAND LIFE APARTMENTS by Hema SukumarHost: Kate Sawyer Twitter: @katesawyer IG: @mskatesawyer Books: The Stranding by Kate Sawyer & This FamilyHema's recommendations:A book for fans of Hema's work: 44 Scotland Street by Alexander McCall Smith, The Single Ladies of Jacaranda Retirement Village by Joanna NellA book Hema has always loved: Malgudi Days by RK NararyanA book that's been published recently or is coming soon: The Twilight Garden by Sara Nisha Adams, Four Seasons in Japan by Nick Bradley, After The Funeral by Tessa HadleyIf you enjoyed this show please do rate, review and share with anyone you think will enjoy it: https://www.spreaker.com/show/novel-experienceNovel Experience with Kate Sawyer is recorded and produced by Kate Sawyer - GET IN TOUCHTo receive transcripts and news from Kate to your inbox please SIGN UP FOR MY NEWSLETTER or visit https://www.mskatesawyer.com/novelexperiencepodcast for more information.Thanks for listening!Kate x

Andariki Namaskaram! Hello Listeners! In this episode, we have the crowd favourite Beanbagg with us to talk about 'Writing'. We compare grey characters from #TamilCinema and #TeluguCinema, and try and see how the different styles work out on the big screen. We discuss #Pudhupettai starring #Dhanush, #Paruthiveeran starring #Karthi and our own #Sukumar's #Pushpa starring #AlluArjun. The comparisons are only for our discussion purposes, treat this episode the same way. #PushpaTheRise #PushpaTheRule #Selvaraghavan #AmeerSultan ------------------------------------------------------------------------------------------------------------------------

A Try to Bring back Our Childhood Memories... The Poems which Cover a Major part of those Times... This Time a Poem of the great Shri Sukumar Ray, "Otiter Chobi 1"... Headphone

He quit his cushy job at Amazon and travelled from 2015 to 2019. He has jumped into lakes and seas in Argentina (more than a few times), watched soaring condors while trekking in the South of Chile (well, one condor but a really majestic one), walked from the end of Switzerland to the end of France, motorcycled for more than a year in India, cycled 6000-8000 kilometres from Tajikistan to Slovenia, become a certified paragliding pilot and mountaineer, and other such cool-sounding stuff. But that is not the only things we will talk about. This week, like our guest Pritam Sukumar, we take the road less travelled. He cycled through Asia and Europe for 9 months, and our conversations ranged from the mindfulness of cycling, and writing about negative travel experiences to the generosity of strangers and the idea of home. Tune in, as we cycle through Pritam's thoughts and experiences of being a citizen of the road. Also check out the following Pritam on Instagram: https://www.instagram.com/pritamps/ Pritam's newsletter on Substack: https://pritamps.substack.com/How Pritam met his wife Ania while volunteering in a farm in Slovenia https://pritamps.substack.com/p/how-i-met-my-wife Racism on the Refugee Trail: https://pritamps.substack.com/p/3-racism-on-the-refugee-trailIf you are intrigued about Central Asia, Samosas and Hospitality, check out the episodes on Uzbekistan Beauty of Uzbekistan and the Geometry Box: https://omny.fm/shows/postcards-from-nowhere-with-utsav-mamoria/beauty-of-uzbekistan-the-geometry-boxMelons of Samarkand: https://omny.fm/shows/postcards-from-nowhere-with-utsav-mamoria/melons-of-samarkand Vincent Van Gogh and Uzbekistan: https://podcasts.adorilabs.com/show/e?eid=I03d1slNCXMla8VCSecrets of Doors: https://podcasts.adorilabs.com/show/e?eid=InTTDLzqdrZWSvf5 Train Journeys and Humanity: Part 1: https://podcasts.adorilabs.com/show/e?eid=I2xUGZmKqpNnFmKl Train Journeys and Humanity: Part 2: https://podcasts.adorilabs.com/show/e?eid=I2fOFK5K0YFNLT3F World's most popular snack: https://podcasts.adorilabs.com/show/e?eid=ImYiIkxnf8vNTFNn For reflections on walking, check out Walking: An Act of Resistance: https://podcasts.adorilabs.com/show/e?eid=IlhRj0aYOdW8A8Pu You can reach out to our host Utsav on Instagram: @‌whywetravel42(https://www.instagram.com/whywetravel42  ) Do follow IVM Podcasts on social media. We are @IVMPodcasts on Facebook, Twitter, & Instagram.  Do share the word with your folks!  See omnystudio.com/listener for privacy information.

A Try to Bring back Our Childhood Memories... The Poems which Cover a Major part of those Times... This Time a Poem of the great Shri Sukumar Ray, "Mahabharat (Aadiparba) Bhisma"... Headphone

In this episode, we spoke with Vinesh Sukumar, the Senior Director of AI and ML product at Qualcomm. Vinesh has a wealth of experience in Product Management and Artificial intelligence and has worked for the likes of Nasa, Intel, Lenovo, and most recently Qualcomm.He is also a member of the board of advisors for the AI forum, and is an AI advisor to San Francisco & California state university!We had a cracking discussion about - His background, which started Nasa in an early AI & Data science capacity through to heading up AI and ML at Qualcomm Who Qualcomm are and why is Generative AI becoming more important for players like Qualcomm?What is behind the rapid rise in importance and demand for a dedicated Product team aligned explicitly to ML and AL What are some of the challenges AI product teams usually face and how is this handled?How do people break into Product management What does the future hold for Generative AI?

Fourth Sunday of Easter - John 10:1-10 - Abundant Life Now Rev. Radhika Sukumar-White (she/her) has been a Minister of the Word in the Uniting Church in Australia since 2016. She is a 2nd-Generation Sri Lankan Tamil Australian, and grew up in Canberra before moving to Sydney to study Physiotherapy, Music and then Theology. Radhika is passionate about leading dynamic and sacred worship, preaching and teaching, and walking alongside individuals in their life and faith journeys. Radhika is currently serving as Ministry Team Leader at Leichhardt Uniting Church, a young, vibrant, justice-oriented community of faith in the Inner West of Sydney, on Gadigal and Wangal land. She serves alongside her husband, who also serves as Chaplain at the University of Sydney. Radhika is also passionate about brunch.

Andariki Namaskaram! Hello Listeners! In this episode, we have Praneeth and Surya back to look at #Sukumar's allegedly "underrated" film #1Nenokkadine starring #MaheshBabu, #KritiSanon and others. ------------------------------------------------------------------------------------------------------------------------

Inside the Mind of a Technology-Driven Marketer Sukumar Muthya is a seasoned marketing technology executive with over 27 years of marketing experience across a variety of industries - from manufacturing to technology. Sukumar is currently the Executive Vice President at Ansira Global - an independent global marketing technology and services firm with clients from automotive, technology, finance & insurance and restaurant businesses, helping in media, ad technology, CRM and loyalty. In this episode Sukumar and Swami discuss: How marketing has transformed over the years Muthya's Journey from Tech to Marketing Balancing Marketing Functions as a CMO The Chief Marketing Officer Meets the Chief Marketing Technologist Skillsets to orchestrate integrated marketing initiatives Reconciling Attribution Across Marketing Channels Marketing in a Cookie-less World Digital Transformation in Manufacturing Best Practices to Build Digital Transformation in Companies Integrated Loyalty at Ansira Global The Ansira Value Proposition Marketing in the Metaverse Non-negotiable skillsets for Future Marketers Book Recommendations in Tech, Martech and Marketing People who Inspired Muthya What does Muthya do off-work? Listen to the podcast on Apple Podcasts | Spotify | Anchor | Google Podcasts | Amazon Music Watch the full video episode on YouTube For show notes and earlier guest interviews, please visit www.contraminds.com To sign up for our weekly newsletter, please visit https://contraminds.substack.com/ Connect with Sukumar: https://www.linkedin.com/in/sukumarmuthya/ Connect with Swami: https://www.linkedin.com/in/sivaraman-swaminathan-9856501/ Connect with Vignesh: https://twitter.com/hrorq Connect with us: LinkedIN: https://www.linkedin.com/company/contraminds/ Instagram: https://www.instagram.com/contraminds/ Facebook: https://www.facebook.com/contraminds Website: www.contraminds.com #DigitalMarketingTechnologies #EnterpriseSoftwareBusiness #ManagementConsulting #DigitalMarketingProcesses #DirectResponse #RelationshipMarketingStrategies #SupplyChain #ProcessImprovement #EnterpriseApplications #StrategicThinking #ProgramManagement #OffShoreDelivery #Adtech #Martech #SukumarMuthya #SivaramanSwaminathan #SwaminathanSivaraman #SuperCMOShow #ContraMindsPodcast

Today we're joined by Vinesh Sukumar, a senior director and head of AI/ML product management at Qualcomm Technologies. In our conversation with Vinesh, we explore how mobile and automotive devices have different requirements for AI models and how their AI stack helps developers create complex models on both platforms. We also discuss the growing interest in text-based input and the shift towards transformers, generative content, and recommendation engines. Additionally, we explore the challenges and opportunities for ML Ops investments on the edge, including the use of synthetic data and evolving models based on user data. Finally, we delve into the latest advancements in large language models, including Prometheus-style models and GPT-4. The complete show notes for this episode can be found at twimlai.com/go/623.

Today's conversation is not with a runner or an ultra-endurance athlete. It's a simpler journey of fitness that an average person struggles with. Most want to look good, feel good, and be healthy. And Sukumar's down-to-earth wit makes his journey personable. He has made it work with persistence. We get behind the scenes on this fascinating journey, starting with wanting to get fit to find a marriage partner and the ensuing quest for fitness thereafter. Chapter timelines 0:00 Intro and background 3:45 The beginnings 8:36 The exercise conundrum 13:03 Stumbling into the WHY 21:45 The top three practices that helped 24:33 The tiny habit method ( freedom from demotivation ) 30:52 Changing food habits 35:07 Concept of Tiny Grit and Reducing procrastination 46:14 What's next is walking around planets 50:38 Fun Q&A round 57:42 The last word

A Try to Bring back Our Childhood Memories... The Poems which Cover a Major part of those Times... This Time a Poem of the great Shri Sukumar Ray, "Chitephonta"... Headphone

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.08.527734v1?rss=1 Authors: Bruening, G. W., Sukumar, S., Courter, R. J., O'Brien, M. K., Ahmed, A. A. Abstract: On any given day, we make countless reaching movements to objects around us. While such ubiquity may suggest uniformity, each movement is actually unique in the speed with which it is made. Some movements are slow, while others are fast. These variations in reach speed have long been known to be influenced by accuracy constraints; we slow down when accuracy demands are high. However, in other forms of movement like walking, metabolic cost is the primary determinant of movement speed. Here we ask, what is the role of metabolic cost in determining speed of reaching movements? First we systematically measure the effect of increasing mass on the metabolic cost of reaching across a range of movement speeds. Next, in a sequence of three experiments, we examine how added mass affects preferred movement speeds in a simple reaching task with increasing accuracy requirements. We find that mass consistently increased metabolic cost and led to slower movements. Yet, intriguingly, preferred reach speeds were faster than metabolically optimal. We then demonstrate how a cost function that, critically, considers both accuracy and metabolic cost can explain preferred movement speeds across the range of conditions tested. Together, these findings provide a unifying framework to explain the combined effects of metabolic cost and accuracy on movement speed, and also highlight the integral role metabolic cost plays in determining many forms of movement. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Last week, India's finance minister Nirmala Sitharaman presented her government's Fiscal Year 2023 budget. As in years past, the entire analyst class has been working overtime to scrutinize the minister's speech and the underlying budget spreadsheets to understand how this government plans to steer the Indian economy in the midst of global headwinds and an important general election in 2024.To discuss this year's budget and all that it means, Milan is joined on the show this week by Sukumar Ranganathan, editor-in-chief of the Hindustan Times. There are few journalists in India who follow budgets more closely or more insightfully.  Milan and Sukumar discuss the government's big infrastructure push, its electoral signaling, and future plans to raise revenue. Plus, the two discuss what we can say definitively about the Modi government's economic philosophy after nine years in office. Prashant Jha, “Budget passes BJP's political test ahead of 2024 elections,” Hindustan Times, February 2, 2023.Roshan Kishore, “Nightwatchman's Budget ahead of elections,” Hindustan Times, February 2, 2023.Abhishek Jha and Roshan Kishore, “The Indian economy: Past, present, future,” Hindustan Times, February 6, 2023. Archana Masih interview with Milan Vaishnav, “‘Adani affair overshadowed Budget's stability, prudence,'” Rediff News, February 6, 2023. 

Grab your free Praying Christian Women scripture journal at www.prayingchristianwomen.com/journal today! Welcome to part 2 of our conversation with Dr. Deepa Sukumar, author of the book "Do Not Be Anxious." Deepa was raised in the Hindu faith, and talks with us about how God revealed the truth of the gospel to her and describes her sometimes difficult journey to becoming a Christian. You can connect with Deepa by e-mailing her at enterhisrest2020@gmail.com, and find her book Do Not Be Anxious on Amazon!

Grab your free Praying Christian Women scripture journal at www.prayingchristianwomen.com/journal today! This week's guest on the podcast is Dr. Deepa Sukumar, author of the book Do Not Be Anxious. Deepa was raised in the Hindu faith, and talks with us about how God revealed the truth of the gospel to her and provided for her in every way throughout her journey to becoming a Christian. NOTE: In this episode the topic of suicide is discussed. You can connect with Deepa by e-mailing her at enterhisrest2020@gmail.com, and find her book Do Not Be Anxious on Amazon!

Continuing on our Movies of 2022 series, Aravind, Dhruv and Ravi go over Pushpa: The Rise - the Sukumar & Allu Arjun blockbuster.

Deepa Sukumar was a Hindu medical student with a successful career ahead of her, but she was actually struggling with doubts, self-worth, and suicidal thoughts. Then, when she was at the end of her rope and ready to end her life, God knocked on the door of her heart. Full show notes and photos here. ++++++++++++ Compelled is a seasonal podcast using gripping, immersive storytelling to celebrate the powerful ways God is transforming Christians around the world. These Christian testimonies are raw, true, and powerful. Be encouraged and let your faith be strengthened! Support the podcast on Patreon and listen to episodes 1 week early! Show notes, emails, and more at CompelledPodcast.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

This is a beautiful testimony! Through her growing up years, Deepa was always trying to keep up performance. She was well educated and excelling in many ways yet she had no peace. Friendship and the reading of God's Word attracted her and drew her in. She traded her hopelessness for life with Christ who promises to never leave and never forsake. You can connect with Deepa through email at enterhisrest2020@gmail.com If you want to discuss something with her via her medical practice go to Grace MD Connect Be sure to check out her devotional, Do Not Be Anxious Ann Dunagan's group (as mentioned in this episode) Mission Minded Women Join Pam's group on Facebook Tending Fields Mom's Group Sign up for Pam's Email list right HERE

Dr. Deepa Sukumar grew up as a Hindu in India. She shares the miraculous story of how the Word of God preached the Gospel to her as an adult and she received the Love which she had been looking for in Jesus.

During Vinesh Sukumar's colorful career he has worked at NASA, Apple, Intel, and a variety of other companies, before finding his way to Qualcomm where he is currently the Head of AI/ML Product Management. In today's conversation, Vinesh shares his experience of developing the camera for the very first iPhone and one of the biggest lessons he learned from working with Steve Jobs. We then discuss what his current role entails and the biggest challenge that he has with it, Qualcomm's approach to sustainability from a hardware, systems and software standpoint, and his thoughts on why edge computing is so important.Key Points From This Episode:An overview of Vinesh's career trajectory, including his experiences at NASA, Apple, and Intel.The focal area of Vinesh's PhD.  Challenges that Vinesh faced while working on cutting edge technology for camera phones.Some of the early AI applications that were used in smartphone cameras. The most important factors to consider when developing cameras for phones.Valuable lessons that Vinesh learned from working with Steve Jobs.What Vinesh's role as Head of AI/ML Product Management at Qualcomm consists of.Why optimization is one of the biggest technical challenges that Vinesh faces in his role at Qualcomm. The four buckets of MLOps. Vinesh explains why edge computing is so important. Benefits of building intelligence into devices rather than requiring a connection to the cloud.Qualcomm's approach to scalability. Why Vinesh is excited about cognitive AI.Tweetables:“Camera became one of the most important features for a consumer to buy a phone. Then visual analytics, AI, deep learning, ML really started seeping into images, and then into videos, and now the most important consumer influencing factor to buy a phone is the camera.” — Vinesh Sukumar [0:07:01]“Reaction time is much better when you have intelligence on the device, rather than giving it to the cloud to make the decision for you.” — Vinesh Sukumar [0:20:48]Links Mentioned in Today's Episode:Vinesh Sukumar on LinkedInQualcomm

Sunday Nonsense presents Sukumar Ray's 'Drighangchu'Narration and second pundit - DeepRajamoshai - MirMan - SomakMontri - AmartyaJollad - AtriOther voices - Saikat, Alankar, Proteep, Biplab, Samrat, Arnab, Ribhu, AltoHolde Shobuj OrangutanLyrics - Sukumar RayComposition, Arrangement, Mixing, Mastering - SayakTabla - Subhadra KalyanVoices - Somak, Sree, GodhuliSound design : RichardPoster design : AsteriscIntroduction, first pundit, daarkaak, recording and episode direction : AgniEnjoy and stay connected with us!!--- Send in a voice message: https://anchor.fm/mirchibanngla/message See acast.com/privacy for privacy and opt-out information. Hosted on Acast. See acast.com/privacy for more information.

Pushpa Trailer Reaction Telugu! Kathy, Mark, and Burk react to the cool Elvis vibe and trailer for Pushpa, a 2021 Indian Telugu-language action drama written and directed by Sukumar. It stars Allu Arjun as the titular character alongside Rashmika Mandanna and Fahadh Faasil (in his Telugu debut). The film depicts the rise of a coolie in the smuggling syndicate of red sanders, a rare wood that grows only in the Seshachalam Hills of Andhra Pradesh state. Our Indian film obsessions continues, unabated! Please continue to send us your Indian film and trailer suggestions!Support the show

There is a conception, or misconception, that journalists are not good at maths. It is rather common to see newspaper headlines and graphics that make basic mathematical and logical errors. On the other hand, in the last decade or so, we have seen a massive rise in “data journalism”. With more and more data being available, journalists are able to write stories exclusively based on data. How do these two square off? To answer this, we have Sukumar Ranganathan, editor in chief of the Hindustan Times. He was previously editor of Mint, of which he was one of the founding editors. It was while he was at Mint that he gave a big push to the then nascent field of “data journalism”, inviting writers such as HowIndiaLives, Rukmini S and myself to write data-backed pieces for Mint. He has previously worked in editorial leadership roles at The Hindu Businessline and Business Today. Sukumar has degrees in chemical engineering, maths, and business administration, and is interested in mathematics, science and technology, the history of business, new media, and data-based political journalism. He reads and collects comic books and is an amateur birder. He tweets under the ID @HT_ed Show Notes: 00:03:15: Are journalists really bad at maths? 00:16:30: Impact of bad data on public policy, and information theory 00:21:00: How data in journalism has changed in the last 20-25 years 00:23:00: The data journalism story 00:31:15: Judging a data story 00:45:30: Advice to budding data journalists Data Chatter is a podcast on all things data. It is a series of conversations with experts and industry leaders in data, and each week we aim to unpack a different compartment of the "data suitcase". The podcast is hosted by Karthik Shashidhar. He is a blogger, newspaper columnist, book author and a former data and strategy consultant. Karthik currently heads Analytics and Business Intelligence for Delhivery, one of India's largest logistics companies. You can follow him on twitter at @karthiks, and read his blog at noenthuda.com

Watch this episode to learn how social pedagogy can help counter hate and the epidemic of “othering." Dr. Vivek Venkatesh is the UNESCO Co-Chair in Prevention of Radicalization and Violent Extremism at Concordia University. In this episode, he speaks about losing his cousin, Sukumar, to an act of terrorism, and how that event catalyzed some of deep inner work and continues to fuel his current passion as a filmmaker, musician, multimedia artist, curator, and applied learning scientist working at the intersection of public pedagogy and critical digital literacy. 0:30 About Vivek Venkatesh 01:55 Vivek's story about losing his cousin, Sukumar, to an act of terrorism 06:50 Having empathy for people who have lost loved ones to acts of terrorism 09:38 Vivek explains how “resilience to hate comes from accepting ‘the other' within ourselves.” 13:07 What is social pedagogy and how can it counter the epidemic of othering? 14:56 About Project SOMEONE 20:25 How Vivek's musical bands (Landscape of Hate and Landscape of Hope) challenge conceptions of hate To watch the video with subtitles: https://www.youtube.com/channel/UC78vaeHVmoxebZCYtqsKe0A CONNECT WITH VIVEK ✩ Life after hate: https://www.youtube.com/watch?v=ylxDwziIYwA ✩ Project SOMEONE's Website: https://projectsomeone.ca ✩ Project SOMEONE's Twitter: @projectsomeone ✩ Chaire UNESCO-PREV's Website: https://chaireunesco-prev.ca ✩ Chaire UNESCO-PREV's Twitter: @unescoprev CONNECT WITH ANITA ✩ Email purposefulempathy@gmail.com ✩ Website https://www.anitanowak.com/ ✩ LinkedInwww.linkedin.com/in/anitanowak ✩ Instagram https://tinyurl.com/anitanowakinstagram ✩ Twitter https://twitter.com/anitanowak21 ✩ Facebook Page https://tinyurl.com/PurposefulEmpathyFacebook ✩ Facebook Group https://tinyurl.com/PurposefulEmpathyCommunity ✩ Podcast Audio https://tinyurl.com/PurposefulEmpathyPodcast This episode was brought to you by Grand Heron International REACH THEM AT ✩ Website: www.grandheroninternational.ca; www.coachingonsite.ca; www.ghi.coach ✩ LinkedIn: https://www.linkedin.com/company/grand-heron-international/ ✩ Facebook: https://www.facebook.com/grandheroninternational/ ✩ Instagram: @Grand_Heron_International ✩ Twitter: @GrandHeronIntl; https://twitter.com/GrandHeronIntl Video Edited by David Tsvariani

Indecisive UW senior Luke Schaefer sits down with data journalist Kavya Sukumar to discuss her transition from working on the Xbox to working in a newsroom. Learn how a career in data journalism might be right for you, how career changes are possible post-college, and how Kavya turned a Game of Thrones binge into a … Continue reading "Data Journalism with Kavya Sukumar (Microsoft, Vox Media)"

In this episode, Dr. Grady and Garrett discuss something that is not talked about a lot in diabetes education, PROTEIN!! That's right, carbs are not the only thing you need to think about when managing blood sugar levels.  We talk about how it can affect blood sugar in both type 1 and type 2 diabetes. We also go over various sources of protein and the advantages and disadvantages of each. PLEASE SUBSCRIBE TO THE PODCAST For more Diabuddies content follow us on The Diabuddies Podcast Facebook page. Twitter: @TheDiabuddies Instagram: @thediabuddiespodcast You can email us at TheDiabuddiesPodcast@gmail.com   Resources/Links Discussed in the episode: Evans, M., et al. “Dietary Protein Affects Both the Dose and Pattern of Insulin Delivery Required to Achieve Postprandial Euglycaemia in Type 1 Diabetes: a Randomized Trial.” Diabetic Medicine, 2018, doi:10.1111/dme.13875. Editor, (2019, January). Type 1 Diabetes study shows dietary protein is linked with additional insulin needs. Retrieved at: https://www.diabetes.co.uk/news/2019/jan/type-1-diabetes-study-shows-dietary-protein-is-linked-with-additional-insulin-need-94221545.html Huang, Z., Wang, Y., Shafer, R., Winn, NC., Kanaley, JA., Vardhanabhuti, B., (2019). Glycemic effects following the consumption of mixed soy protein isolate and alginate beverages in healthy adults. Food and Function; 10(3): 1718-1725. doi: 10.1039/c8fo01627e. Natarajan Sulochana, K., Lakshmi, S., Punitham, R., Arokiasamy, T., Sukumar, B., & Ramakrishnan, S., (2002). Effects of oral supplementation of free amino acids in type 2 diabetic patients – a pilot clinical trail. Med Sci Monit; 8(3): CR131-7. Pubmed ID: 11887024. Srinivasan, V., Radhakrishnan, S., Angayarkanni, N, & Sulochana, KN., (2019). Antidiabetic effect of free amino acids supplementation in human visceral adipocytes through adiponecting dependent mechanism. Indian J Med Res; 149(1): 41-46. doi: 10.4103/ijmr.IJMR_1782_16.

Over the decades, India's political leadership has had a complicated relationship with scientific innovations. Arun Sukumar, the head of the technology initiative at the Observer Research Foundation of New Delhi joins Sandip to discuss pivotal moments in India's tech history, how Prime Minister Modi sold Indians "a lethal cocktail of faith and technology" and more.